RxDoctor Payments Data

Jesse Smith, MD

Retina Specialist · Denver, CONPI 1407142151

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,320 of the $6,835 with a category attached, or 77.8%. AbbVie accounts for 77.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $5,342 and has fallen 99.4% since, to $30 in 2025.

$6,835in general payments, 2019–2025

Across 18 payments — averaging $379.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Dutch Ophthalmic, USA$780
  • Genentech USA, Inc.$228
  • Oculus Surgical Inc.$204
  • Astellas Pharma US Inc$160
  • Kala Pharmaceuticals, Inc.$121
  • plus $22 from 1 others
$16,640in research payments, 2019–2025

Across 1 payment — averaging $16,640 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$17K

What the payments were for

  • Consulting fees$5,32078%
  • Food & beverage$1,51522%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,835 in reported general payments places this provider in the 60th percentile of 51 retina specialist providers in Colorado.

See all retina specialist providers in Colorado

Medicare billing

Part B allowed, 2024
$248,727
Medicare patients
714
Services billed
3,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine21$9,624
Cyclosporine12$3,798
Fluorometholone39$2,897
Prednisolone Acetate34$1,419
Latanoprost46$716
Brimonidine Tartrate35$550
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$391
Ketorolac Tromethamine25$280
ErythromycinErythromycin Base15$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$5,320$9,62421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 51 retina specialist providers in Colorado.

Other retina specialist in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →